Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy ; volume:22 ; number:1 ; day:30 ; month:8 ; year:2023 ; pages:1-15 ; date:12.2023
Molecular cancer ; 22, Heft 1 (30.8.2023), 1-15, 12.2023
- Urheber
-
Sordo-Bahamonde, Christian
Lorenzo-Herrero, Seila
Granda-Díaz, Rocío
Martínez-Pérez, Alejandra
Aguilar-García, Candelaria
Rodrigo, Juan P.
García-Pedrero, Juana M.
Gonzalez, Segundo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-023-01845-4
- URN
-
urn:nbn:de:101:1-2023110810132398225950
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sordo-Bahamonde, Christian
- Lorenzo-Herrero, Seila
- Granda-Díaz, Rocío
- Martínez-Pérez, Alejandra
- Aguilar-García, Candelaria
- Rodrigo, Juan P.
- García-Pedrero, Juana M.
- Gonzalez, Segundo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy